Ferinject
Generic Name
Ferric Carboxymaltose
Manufacturer
Vifor Pharma
Country
Switzerland
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| ferinject 500 mg injection | ৳ 3,430.00 | N/A |
Description
Overview of the medicine
Ferinject 500 mg Injection is an intravenous iron preparation used for the treatment of iron deficiency when oral iron is ineffective or cannot be used. It delivers iron in a stable form directly into the bloodstream to replenish iron stores and increase hemoglobin levels.
Uses & Indications
Dosage
Adults
Total cumulative dose determined by baseline hemoglobin and body weight. Maximum single dose of 1000 mg iron (20 mL) not exceeding 15 mg iron/kg body weight. Doses greater than 500 mg should be infused over at least 15 minutes.
Elderly
No specific dosage adjustment needed, similar to adults.
Renal_impairment
No specific dose adjustment required. Caution in patients with severe renal impairment.
How to Take
Administered by intravenous infusion only by a healthcare professional. Can be given as a slow intravenous injection or diluted in 0.9% sodium chloride solution for infusion. The infusion rate depends on the dose.
Mechanism of Action
Ferric carboxymaltose is an iron carbohydrate complex that releases iron for transport to iron storage proteins (ferritin) and iron transport proteins (transferrin). The iron is then utilized for hemoglobin synthesis in red blood cells.
Pharmacokinetics
Onset
Hemoglobin response typically observed within 2-4 weeks; ferritin levels increase rapidly.
Excretion
Excess iron is primarily stored in the reticuloendothelial system; minimal renal excretion.
Half life
Terminal half-life is approximately 7-12 hours.
Absorption
Complete bioavailability upon intravenous administration.
Metabolism
Iron is separated from the carbohydrate complex and primarily incorporated into ferritin or transferrin.
Side Effects
Contraindications
- Hypersensitivity to ferric carboxymaltose or any of its excipients.
- Anemia not attributed to iron deficiency (e.g., hemolytic anemia).
- Evidence of iron overload or disturbances in iron utilization.
- First trimester of pregnancy.
Drug Interactions
Oral Iron Preparations
Concurrent administration of oral iron preparations may reduce their absorption. Oral iron should be initiated only after the course of Ferinject is completed.
Other Parenteral Iron Products
Should not be administered concomitantly.
Storage
Store below 30°C. Do not freeze. Keep the vial in the outer carton to protect from light. Do not use if particles are visible or if the solution is cloudy.
Overdose
Iron overdose can lead to iron accumulation in storage sites, potentially causing hemosiderosis. Treatment is symptomatic and may include iron chelation therapy (e.g., deferoxamine) if severe.
Pregnancy & Lactation
Use with caution during the second and third trimesters of pregnancy only if clearly needed and the potential benefit outweighs the potential risk. Contraindicated in the first trimester. Minimal transfer into breast milk, benefits of breastfeeding should be weighed against potential risks.
Side Effects
Contraindications
- Hypersensitivity to ferric carboxymaltose or any of its excipients.
- Anemia not attributed to iron deficiency (e.g., hemolytic anemia).
- Evidence of iron overload or disturbances in iron utilization.
- First trimester of pregnancy.
Drug Interactions
Oral Iron Preparations
Concurrent administration of oral iron preparations may reduce their absorption. Oral iron should be initiated only after the course of Ferinject is completed.
Other Parenteral Iron Products
Should not be administered concomitantly.
Storage
Store below 30°C. Do not freeze. Keep the vial in the outer carton to protect from light. Do not use if particles are visible or if the solution is cloudy.
Overdose
Iron overdose can lead to iron accumulation in storage sites, potentially causing hemosiderosis. Treatment is symptomatic and may include iron chelation therapy (e.g., deferoxamine) if severe.
Pregnancy & Lactation
Use with caution during the second and third trimesters of pregnancy only if clearly needed and the potential benefit outweighs the potential risk. Contraindicated in the first trimester. Minimal transfer into breast milk, benefits of breastfeeding should be weighed against potential risks.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 3 years from the date of manufacture. Refer to product label for exact expiry date.
Availability
Available in hospitals, clinics, and pharmacies
Approval Status
Approved by regulatory bodies worldwide, including EMA and FDA (as Injectafer)
Patent Status
Patented by Vifor Pharma
Clinical Trials
Extensive clinical trials (e.g., FIND-CKD, REPAIR-IDA) have demonstrated the efficacy and safety of ferric carboxymaltose in various patient populations with iron deficiency anemia, including those with chronic kidney disease, inflammatory bowel disease, and postpartum iron deficiency.
Lab Monitoring
- Hemoglobin (Hb) and ferritin levels should be monitored regularly to assess treatment response and prevent iron overload.
- Transferrin saturation (TSAT) may also be monitored.
- Phosphorus levels should be monitored due to risk of hypophosphatemia.
Doctor Notes
- Always assess total body iron deficit and patient iron status (Hb, ferritin, TSAT) before and during treatment.
- Closely monitor patients for hypersensitivity reactions during and for at least 30 minutes after each administration.
- Ensure proper dilution and infusion rate as per guidelines to minimize adverse effects and ensure patient safety.
- Consider phosphorus monitoring with repeated doses.
Patient Guidelines
- Inform your doctor about all medical conditions, current medications, and allergies, especially to iron preparations.
- Report any adverse reactions, such as dizziness, rash, or breathing difficulties, during or after the infusion immediately.
- Do not take oral iron preparations without consulting your doctor after Ferinject treatment.
Missed Dose Advice
As Ferinject is administered by a healthcare professional, a missed dose should be rescheduled with your doctor or nurse as soon as possible.
Driving Precautions
Ferinject may cause dizziness or lightheadedness. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a balanced diet to support iron levels after treatment, as advised by your healthcare provider.
- Attend all scheduled follow-up appointments for monitoring your iron status.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Ferinject Brand
Other medicines available under the same brand name
